Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE StudyHoward S. Höchster, Eric Hedrick, Lowell L. Hart et al.|Journal of Clinical Oncology|2008Cited by 623
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric‐Bernstam, John D. Hainsworth, Vaikunth Cuchelkar et al.|The Lancet Oncology|2019Cited by 564
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket StudyJohn D. Hainsworth, Razelle Kurzrock|Journal of Clinical Oncology|2018Cited by 500
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)Dana E. Rathkopf, Fred Saad, Matthew R. Smith et al.|European Urology|2014Cited by 273
A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1)J. Randolph Hecht, Christian Jacques, Tanja Trarbach et al.|Journal of Clinical Oncology|2005Cited by 201